Bristol Myers, Bluebird Gets FDA OK for Abecma in Multiple Myeloma
March 29 2021 - 7:53AM
Dow Jones News
By Colin Kellaher
Bristol Myers Squibb Co. and bluebird bio Inc. said the U.S.
Food and Drug Administration approved Abecma for the treatment of
adults with the blood cancer multiple myeloma.
The companies said the approval covers the CAR T cell
immunotherapy formerly known as idecabtagene vicleucel, or ide-cel,
for adults with relapsed or refractory multiple myeloma after four
or more prior lines of therapy.
New York-based Bristol Myers and bluebird, a Cambridge, Mass.,
biotechnology company, are jointly developing and commercializing
Abecma in the U.S. For bluebird, the FDA nod marks its first
approved treatment in oncology and first approved treatment in the
U.S.
Shares of bluebird, which closed Friday at $29.98, rose more
than 9% in premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 29, 2021 07:38 ET (11:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Mar 2024 to Apr 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Apr 2023 to Apr 2024
